Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)

被引：0
|
作者：
Kiver, Verena [1 ]
Hamilton, Erika [2 ]
Tsurutani, Junji [3 ]
Curigliano, Giuseppe [4 ]
Martin, Miguel [5 ]
O'sullivan, Ciara [6 ]
Sohn, Joo Hyuk [7 ]
Tryfonidis, Konstantinos [8 ]
Santarpia, Libero [9 ]
Yang, Shan [9 ]
Dieras, Veronique [10 ]
机构：
[1] Charite Univ Med Berlin, Berlin, Germany
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Showa Univ, Adv Canc Translat Res Inst, Tokyo, Japan
[4] Univ Milan, European Inst Oncol, IRCCS, Milan, Italy
[5] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
[6] Mayo Clin, Rochester, MN USA
[7] Yonsei Canc Ctr, Seoul, South Korea
[8] Merck & Co Inc, Rahway, NJ USA
[9] Seagen Inc, Bothell, WA USA
[10] Eugene Marquis Ctr, Rennes, France
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2024年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
762
引用
收藏
页码：39 / 39
页数：1
相关论文
共 50 条
  • [11] Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+metastatic breast cancer with brain metastases (HER2CLIMB).
    Lin, Nancy U.
    Murthy, Rashmi Krishna
    Anders, Carey K.
    Borges, Virginia F.
    Hurvitz, Sara A.
    Loi, Sherene
    Abramson, Vandana G.
    Bedard, Philippe L.
    Oliveira, Mafalda
    Zelnak, Amelia Bruce
    DiGiovanna, Michael
    Bachelot, Thomas
    Chien, Amy Jo
    O'Regan, Ruth
    Wardley, Andrew M.
    Mueller, Volkmar
    Carey, Lisa A.
    McGoldrick, Suzanne M.
    An, Grace
    Winer, Eric P.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [12] Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+metastatic breast cancer with and without brain metastases (HER2CLIMB)
    Curigliano, G.
    Murthy, R.
    Loi, S.
    Okines, A.
    Paplomata, E.
    Hamilton, E.
    Hurvitz, S. A.
    Cameron, D.
    Borges, V.
    Bedard, P.
    Oliveira, M.
    Jakobsen, E. H.
    Bachelot, T.
    Shachar, S. S.
    Mueller, V.
    Carey, L. A.
    Loibl, S.
    Feng, W.
    Walker, L. N.
    Winer, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S62 - S63
  • [13] Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with pretreated HER2+metastatic breast cancer with and without brain metastases (HER2CLIMB)
    Mueller, V
    Curigliano, G.
    Borges, V
    Hamilton, E.
    Hurvitz, S.
    Loi, S.
    Murthy, R.
    Okines, A.
    Paplomata, E.
    Cameron, D.
    Carey, L. A.
    Gelmon, K.
    Hortobagyi, G.
    Krop, I
    Loibl, S.
    Pegram, M.
    Slamon, D.
    Ramos, J.
    Feng, W.
    Winer, E.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 133 - 134
  • [14] Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+metastatic breast cancer with and without brain metastases (HER2CLIMB).
    Curigliano, Giuseppe
    Mueller, Volkmar
    Borges, Virginia F.
    Hamilton, Erika P.
    Hurvitz, Sara A.
    Loi, Sherene
    Murthy, Rashmi Krishna
    Okines, Alicia Frances Clare
    Paplomata, Elisavet
    Cameron, David A.
    Carey, Lisa A.
    Gelmon, Karen A.
    Hortobagyi, Gabriel N.
    Krop, Ian E.
    Loibl, Sibylle
    Pegram, Mark D.
    Slamon, Dennis J.
    Ramos, Jorge
    Zhang, Chiyu
    Winer, Eric P.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [15] Tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2+metastatic breast cancer (MBC) with brain metastases (BM) (HER2CLIMB)
    Mueller, V
    Lin, N.
    Murthy, R.
    Anders, C.
    Borges, V
    Hurvitz, S.
    Loi, S.
    Abramson, V
    Bedard, P.
    Oliveira, M.
    Zelnak, A.
    Di Giovanna, M.
    Bachelot, T.
    Chien, A. J.
    O'Regan, R.
    Wardley, A.
    Carey, L.
    McGoldrick, S.
    An, X.
    Winer, E. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 161 - 161
  • [16] Study of the combination gemcitabine and trastuzumab in the treatment of HER2+metastatic breast cancer
    Menjon-Beltran, S.
    Olivencia-Dueso, R.
    Gonzalez-Jimenez, E.
    Titos, M. J.
    BREAST CANCER RESEARCH, 2007, 9 (01)
  • [17] THE CHALLENGE OF VALUE-BASED PRICING IN COMBINATION THERAPY:THE CASE OF TRASTUZUMAB AND PERTUZUMAB IN HER2+METASTATIC BREAST CANCER
    Jiao, B.
    Garrison, L. P.
    VALUE IN HEALTH, 2020, 23 : S34 - S35
  • [18] The challenge of value-based pricing in combination therapy: the case of trastuzumab and pertuzumab in HER2+metastatic breast cancer
    Jiao, Boshen
    Garrison, Louis P., Jr.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (03) : 495 - 502
  • [19] Phase I/II trial of ruxolitinib in combination with trastuzumab in HER2+metastatic breast cancer (MBC)
    Kalinsky, Kevin
    Lee, Shing
    Tiersten, Amy
    Makower, Della F.
    Cigler, Tessa
    Franks, Lauren
    Mundi, Prabhjot
    Chi, Dow-Chung
    Blumberg, Lauren
    Sender, Naomi
    Galazyn, Magdalena
    Hosi, Kristina
    Goel, Anupama
    Klein, Paula
    Andreopoulou, Eleni
    Sparano, Joseph
    Crew, Katherine D.
    Califano, Andrea
    Silva, Jose
    Hershman, Dawn L.
    CANCER RESEARCH, 2020, 80 (04)
  • [20] Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial
    Okines, Alicia F. C.
    Curigliano, Giuseppe
    Mizuno, Nobumasa
    Oh, Do-Youn
    Rorive, Andree
    Soliman, Hatem
    Takahashi, Shunji
    Bekaii-Saab, Tanios
    Burkard, Mark E.
    Chung, Ki Y.
    Debruyne, Philip R.
    Fox, Jenny R.
    Gambardella, Valentina
    Gil-Martin, Marta
    Hamilton, Erika P.
    Monk, Bradley J.
    Nakamura, Yoshiaki
    Nguyen, Danny
    O'Malley, David M.
    Olawaiye, Alexander B.
    Pothuri, Bhavana
    Reck, Martin
    Sudo, Kazuki
    Sunakawa, Yu
    Van Marcke, Cedric
    Yu, Evan Y.
    Ramos, Jorge
    Tan, Sherry
    Bieda, Mark
    Stinchcombe, Thomas E.
    Pohlmann, Paula R.
    NATURE MEDICINE, 2025, : 909 - 916
12345